^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT114

    i
    Other names: BNT114, IVAC Warehouse, IVAC_W_bre1_uID, IVAC W bre1 uID
    Associations

    News

    Trials
    Company:
    BioNTech
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    10ms
    TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov)
    P1, N=42, Completed, BioNTech SE | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    BNT114 • IVAC_M_uID
    3years
    TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, BioNTech SE | Trial completion date: Nov 2020 --> Dec 2023
    Clinical • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    BNT114 • IVAC_M_uID
    over4years
    TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, Biontech SE | Trial completion date: Apr 2020 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    BNT114 • IVAC_M_uID